Johnson & Johnson [JNJ] vs Amgen [AMGN] Detailed Stock Comparison

Johnson & Johnson

NYSE
Loading...

Amgen Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Johnson & Johnson wins in 11 metrics, Amgen Inc. wins in 10 metrics, with 0 ties. Johnson & Johnson appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Johnson & Johnson Amgen Inc. Better
P/E Ratio (TTM) 20.49 24.22 Johnson & Johnson
Price-to-Book Ratio 6.68 21.46 Johnson & Johnson
Debt-to-Equity Ratio 60.50 640.28 Johnson & Johnson
PEG Ratio 0.42 0.22 Amgen Inc.
EV/EBITDA 16.84 13.97 Amgen Inc.
Profit Margin (TTM) 21.83% 20.98% Johnson & Johnson
Operating Margin (TTM) 26.72% 30.55% Amgen Inc.
EBITDA Margin (TTM) 26.72% 30.55% Amgen Inc.
Return on Equity 32.87% 106.10% Amgen Inc.
Return on Assets (TTM) 13.46% 7.93% Johnson & Johnson
Free Cash Flow (TTM) $19.31B $8.10B Johnson & Johnson
Dividend Yield 2.09% 3.30% Amgen Inc.
1-Year Return 53.32% 20.32% Johnson & Johnson
Price-to-Sales Ratio (TTM) 5.66 5.06 Amgen Inc.
Enterprise Value $574.25B $232.21B Johnson & Johnson
EV/Revenue Ratio 5.96 6.32 Johnson & Johnson
Gross Profit Margin (TTM) 67.56% 69.84% Amgen Inc.
Revenue per Share (TTM) $40 $68 Amgen Inc.
Earnings per Share (Diluted) $11.04 $14.24 Amgen Inc.
Beta (Stock Volatility) 0.33 0.47 Johnson & Johnson
Short % of Float 1.03% 2.60% Johnson & Johnson

Johnson & Johnson vs Amgen Inc. Stock Performance Analysis

Loading Price Chart...

JNJ
AMGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Johnson & Johnson-2.16%1.51%3.95%-3.10%10.03%13.65%
Amgen Inc.-1.31%1.39%7.42%-4.29%7.75%6.99%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Johnson & Johnson53.32%46.67%48.70%108.58%263.36%290.52%
Amgen Inc.20.32%54.66%48.82%137.40%512.31%431.58%

Performance & Financial Health Analysis: Johnson & Johnson vs Amgen Inc.

MetricJNJAMGN
Market Information
Market Cap i$555.84B$187.93B
Market Cap CategoryMega capLarge cap
10 Day Avg. Volume i8,370,5662,431,753
90 Day Avg. Volume i7,752,9652,596,291
Last Close$235.66$350.53
52 Week Range$149.04 - $251.71$267.83 - $391.29
% from 52W High-6.38%-10.42%
All-Time High$251.71 (Mar 02, 2026)$391.29 (Mar 02, 2026)
% from All-Time High-6.38%-10.42%
Growth Metrics
Quarterly Revenue Growth0.10%0.09%
Quarterly Earnings Growth-0.52%1.13%
Financial Health
Profit Margin (TTM) i0.22%0.21%
Operating Margin (TTM) i0.27%0.31%
Return on Equity (TTM) i0.33%1.06%
Debt to Equity (MRQ) i60.50640.28
Cash & Liquidity
Book Value per Share (MRQ)$33.87$16.07
Cash per Share (MRQ)$8.34$16.94
Operating Cash Flow (TTM) i$22.21B$9.96B
Levered Free Cash Flow (TTM) i$43.47B$7.50B
Dividends
Last 12-Month Dividend Yield i2.09%3.30%
Last 12-Month Dividend i$5.20$12.18

Valuation & Enterprise Metrics Analysis: Johnson & Johnson vs Amgen Inc.

MetricJNJ (Apr 24, 2026)AMGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i20.4924.22
Forward P/E i17.8014.77
PEG Ratio i0.420.22
Price to Sales (TTM) i5.665.06
Price to Book (MRQ) i6.6821.46
Market Capitalization
Market Capitalization i$555.84B$187.93B
Enterprise Value i$574.25B$232.21B
Enterprise Value Metrics
Enterprise to Revenue i5.966.32
Enterprise to EBITDA i16.8413.97
Risk & Other Metrics
Beta i0.330.47
Book Value per Share (MRQ) i$33.87$16.07

Financial Statements Comparison: Johnson & Johnson vs Amgen Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricJNJ (2025)AMGN (2025)
Revenue/Sales i94.19B36.75B
Cost of Goods Sold i30.26B12.04B
COGS % of Revenue i32.1%32.8%
Gross Profit i63.94B24.71B
Gross Margin i67.9%67.2%
Research & Development i14.67B7.27B
Operating Income (EBIT) i25.60B9.08B
Operating Margin i27.2%24.7%
EBITDA i35.16B16.90B
EBITDA Margin i37.3%46.0%
Pre-Tax Income i32.58B8.98B
Pre-Tax Income % of Revenue i34.6%24.4%
Income Tax i5.78B1.27B
Income Tax % of Revenue i6.1%3.4%
Net Income (Profit) i26.80B7.71B
Profit Margin i28.5%21.0%

Balance Sheet & Liquidity Metrics

MetricJNJ (2025)AMGN (2025)
Cash & Equivalents i19.71B9.13B
Total Current Assets i55.62B29.06B
Total Current Assets % of Revenue i59.1%79.1%
Total Current Liabilities i54.13B25.49B
Total Current Liabilities % of Revenue i57.5%69.4%
Long-Term Debt i39.44B50.01B
Long-Term Debt % of Revenue i41.9%136.1%
Total Shareholders Equity i81.54B8.66B
Retained Earnings iN/A-25.11B
Retained Earnings % of Revenue i0.0%-68.3%
Property, Plant & Equipment i05.22B

Cash Flow Statement Comparison

MetricJNJ (2025)AMGN (2025)
Operating Cash Flow i22.21B10.51B
Operating Cash Flow % of Revenue i23.6%28.6%
Capital Expenditures i-4.83B-1.86B
Free Cash Flow i19.31B8.10B
FCF Margin i20.5%22.0%
Debt Repayment i-14.09B-5.00B
Common Stock Repurchase i-5.95B0

Short Interest & Institutional Ownership Analysis

MetricJNJAMGN
Shares Short i22.27M13.98M
Short Ratio i2.905.43
Short % of Float i1.03%2.60%
Shares Outstanding i2.41B538.80M
Float Shares i2.41B537.62M
% Held by Insiders i0.06%0.22%
% Held by Institutions i75.84%85.36%
% Held by Public i24.10%14.42%

Dividend Analysis & Yield Comparison: Johnson & Johnson vs Amgen Inc.

MetricJNJAMGN
Last 12-Month Dividend i$5.20$12.18
Last 12-Month Dividend Yield i2.09%3.30%
3-Year Avg Annual Dividend i$4.97$9.98
3-Year Avg Dividend Yield i0.74%0.77%
3-Year Total Dividends i$14.92$29.95
Ex-Dividend DateFeb 24, 2026May 15, 2026